Hantavirus outbreak lifts Moderna, Emergent and BioNTech

A hantavirus outbreak on the cruise ship MV Hondius renewed investor interest in pandemic-preparation stocks in early May, driving a short-term rally in Moderna and renewed attention on Emergent BioSolutions and BioNTech. Traders and market participants cited company results, program updates and technical chart levels as factors in the moves.

Moderna’s shares rose from $43.69 on May 1 to $59.45 on May 11, an increase of about 36%, with trading volume rising alongside the price. The company reported first-quarter 2026 revenue of $389 million, up 260% year over year, and disclosed a collaboration with the U.S. Army Medical Research Institute of Infectious Diseases on a hantavirus vaccine. Moderna also published Phase 3 data for its mRNA-1010 influenza program in a peer-reviewed medical journal. The company recorded an $878 million litigation settlement with Arbutus in the period.

Technical traders identified a cup-and-handle pattern for Moderna. The cup bottom was near $43.69 and the rim around $59.45, with a short-term consolidation near $54.05. Short-term support was cited at roughly $51.17 and a breakout level at $60.96. Analysts who track chart patterns calculate a projected measured target near $81.46 if the stock clears the cited breakout level. A close below $43.69 would invalidate the pattern in the view of these traders.

Emergent BioSolutions, which produced Johnson & Johnson’s COVID-19 vaccine at a Baltimore plant under a prior contract, reported first-quarter 2026 revenue of $156.1 million, down about 30% from a year earlier. The company’s 2026 revenue guidance issued earlier in the year was below consensus estimates. Emergent’s stock fell about 44% earlier in the year, from $14.07 to $7.53, following the guidance and the revenue decline. The company previously experienced a 2021 contamination incident that destroyed about 15 million vaccine doses.

Chart observers described an inverse head-and-shoulders base for Emergent, with a left shoulder near $7.82, a head at $7.53 and a right shoulder around $8.33. The neckline was noted near $10.02; a daily close above that level would complete the pattern and point to a calculated upside target near $12.65. A daily close below $7.53 would be considered a failure of the base.

BioNTech reported a first-quarter 2026 net loss of $2.28 per share and revenue of €138 million, down about 28% from a year earlier. The company affirmed full-year 2026 sales guidance in a range of €2.328 billion to €2.678 billion. Since March 10, BioNTech’s price action has formed a standard head-and-shoulders pattern, with a left shoulder near $100, a head at $113.55 and a right shoulder around $93.63, above a neckline near $92.39.

Options volume showed a higher proportion of put activity for BioNTech, with a put-call ratio by volume of about 2.23 and by open interest about 1.15. Market technicians noted that a daily close below $92.39 would confirm a breakdown toward $86.64 and lower supports near $79.31 and $72.36. A move above $100.47 would begin to negate the right shoulder, and a move above $113.55 would erase the head-and-shoulders pattern.

Market participants said the hantavirus incident on MV Hondius was the immediate catalyst that focused short-term attention on companies tied to mRNA platforms and biodefense. Traders and chart analysts highlighted the technical levels in May 2026 as the points that would determine whether the recent rallies continue or reverse.